|
|
Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase |
Lanping Xu1, Huanling Zhu2, Jianda Hu3, Depei Wu4, Hao Jiang1, Qian Jiang1, Xiaojun Huang1() |
1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China 2. West China Hospital, Sichuan University, Chengdu 610041, China 3. Fujian Medical University Union Hospital, Fujian Institute of Hematology, Fuzhou 350001, China 4. The First Affiliated Hospital, Soochow University, Suzhou 215006, China |
|
|
Abstract In the tyrosine kinase inhibitor (TKI) era, imatinib is the first-line therapy for patients with chronic myeloid leukemia (CML) in chronic or accelerated phase. Although second-generation TKIs (TKI2), including dasatinib and nilotinib, are appropriate treatment regimens for patients with disease that progressed to accelerated phase following imatinib therapy, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative therapy. This study retrospectively analyzed the efficacy of TKI2 and HSCT for treatment of CML in accelerated phase. Ninety-three patients with CML registered in the Chinese CML alliance database from February 2001 to February 2014 were enrolled and divided into the TKI2 (n = 33) and allo-HSCT (n = 60) groups. In the TKI2 group, 26 and 7 patients received nilotinib and dasatinib, respectively, as initial TKI2 and 11 patients transferred to the alternative TKI2 after failure to one TKI2. In the allo-HSCT group, 22 (36.7%), 35 (58.3%), and 3 (10%) patients underwent allo-HSCT from an HLA-matched sibling donor, HLA mismatched/haploidentical donor, and unrelated donor, respectively. All patients in the HSCT group were engrafted. Overall, 69.7%, 48.5%, and 45.5% of patients presented hematological, cytogenetic, and major molecular responses, respectively, to at least one of TKI2. All 60 patients (100%) achieved CHR and cytogenetic response in the HSCT group. Patients in the TKI2 group exhibited lower 5-year overall survival rate (42.9% vs. 86.4%, P = 0.002), 5-year event-free survival rate (14.3% vs. 76.1%, P<0.001), and 5-year progression-free survival (28.6% vs. 78.1%, P<0.001) than those in the allo-HSCT group. Multivariate analysis showed that male sex and TKI2 therapy were predictors of poor overall survival, whereas hemoglobin<100 g/L and TKI2 therapy were predictors of poor event-free survival and progression-free survival. These results indicated that allo-HSCT may be superior to nilotinib and dasatinib for adult patients with CML in accelerated phase.
|
Keywords
chronic myeloid leukemia
imatinib
dasatinib
nilotinib
allogeneic hematopoietic stem cell transplantation
|
Corresponding Author(s):
Xiaojun Huang
|
Online First Date: 23 June 2015
Issue Date: 26 August 2015
|
|
1 |
CL Sawyers. Chronic myeloid leukemia. N Engl J Med 1999; 340(17): 1330–1340
https://doi.org/10.1056/NEJM199904293401706
pmid: 10219069
|
2 |
JM Goldman, JV Melo. Chronic myeloid leukemia—advances in biology and new approaches to treatment. N Engl J Med 2003; 349(15): 1451–1464
https://doi.org/10.1056/NEJMra020777
pmid: 14534339
|
3 |
A Gratwohl, R Brand, J Apperley, C Crawley, T Ruutu, P Corradini, E Carreras, A Devergie, C Guglielmi, HJ Kolb, D Niederwieser; Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006; 91(4): 513–521
pmid: 16533723
|
4 |
National Marrow Donor Program. Disease and transplant outcome data, NMDP-facilitated transplant outcomes.
|
5 |
S Saussele, M Lauseker, A Gratwohl, DW Beelen, D Bunjes, R Schwerdtfeger, HJ Kolb, AD Ho, C Falge, E Holler, G Schlimok, AR Zander, R Arnold, L Kanz, R Dengler, C Haferlach, B Schlegelberger, M Pfirrmann, MC Müller, S Schnittger, A Leitner, N Pletsch, A Hochhaus, J Hasford, R Hehlmann; German CML Study Group. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010; 115(10): 1880–1885
https://doi.org/10.1182/blood-2009-08-237115
pmid: 19965667
|
6 |
Q Jiang, LP Xu, DH Liu, KY Liu, SS Chen, B Jiang, H Jiang, H Chen, YH Chen, W Han, XH Zhang, Y Wang, YZ Qin, YR Liu, YY Lai, XJ Huang. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood 2011; 117(11): 3032–3040
https://doi.org/10.1182/blood-2010-09-308510
pmid: 21252092
|
7 |
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines ) : chronic myelogenous leukemia. Version 2. 2014.
|
8 |
P Le Coutre, OG Ottmann, F Giles, DW Kim, J Cortes, N Gattermann, JF Apperley, RA Larson, E Abruzzese, SG O'Brien, K Kuliczkowski, A Hochhaus, FX Mahon, G Saglio, M Gobbi, YL Kwong, M Baccarani, T Hughes, G Martinelli, JP Radich, M Zheng, Y Shou, H Kantarjian. Nilotinib (formly AMN 107), a highly selective BCR-ABL tyosine kinase inhibitor, is active in patients with imatinib-resistant or-intolerant accelerated-phase chronic mylogenous leukemia. Blood 2008; 111: 1834–1839
pmid: 18048643
|
9 |
PD Le Coutre, FJ Giles, A Hochhaus, JF Apperley, GJ Ossenkoppele, R Blakesley, Y Shou, NJ Gallagher, M Baccarani, J Cortes, HM Kantarjian. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia 2012; 26(6): 1189–1194
https://doi.org/10.1038/leu.2011.323
pmid: 22076466
|
10 |
F Guilhot, J Apperley, DW Kim, EO Bullorsky, M Baccarani, GJ Roboz, S Amadori, CA de Souza, JH Lipton, A Hochhaus, D Heim, RA Larson, S Branford, MC Muller, P Agarwal, A Gollerkeri, M Talpaz. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in accelerated phase. Blood 2007; 109(10): 4143–4150
https://doi.org/10.1182/blood-2006-09-046839
pmid: 17264298
|
11 |
JF Apperley, JE Cortes, DW Kim, L Roy, GJ Roboz, G Rosti, EO Bullorsky, E Abruzzese, A Hochhaus, D Heim, CA de Souza, RA Larson, JH Lipton, HJ Khoury, HJ Kim, C Sillaber, TP Hughes, P Erben, J Van Tornout, RM Stone. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J Clin Oncol 2009; 27(21): 3472–3479
https://doi.org/10.1200/JCO.2007.14.3339
pmid: 19487385
|
12 |
DP Lu, L Dong, T Wu, XJ Huang, MJ Zhang, W Han, H Chen, DH Liu, ZY Gao, YH Chen, LP Xu, YC Zhang, HY Ren, D Li, KY Liu. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006; 107(8): 3065–3073
https://doi.org/10.1182/blood-2005-05-2146
pmid: 16380454
|
13 |
XJ Huang, DH Liu, KY Liu, LP Xu, H Chen, W Han, YH Chen, JZ Wang, ZY Gao, YC Zhang, Q Jiang, HX Shi, DP Lu. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006; 38(4): 291–297
https://doi.org/10.1038/sj.bmt.1705445
pmid: 16883312
|
14 |
XJ Huang, DH Liu, KY Liu, LP Xu, H Chen, W Han, YH Chen, XH Zhang, DP Lu. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant 2009; 15(2): 257–265
https://doi.org/10.1016/j.bbmt.2008.11.025
pmid: 19167686
|
15 |
XJ Huang, LP Xu, KY Liu, DH Liu, Yu Wang, Huan Chen, YH Chen, Wei Han, JZ Wang, Yao Chen, XH Zhang, HX Shi, FR Wang, FF Tang. Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies. Clin Cancer Res 2009; 15(14): 4777–4783
https://doi.org/10.1158/1078-0432.CCR-09-0691
pmid: 19584148
|
16 |
Y Wang, YJ Chang, LP Xu, KY Liu, DH Liu, XH Zhang, H Chen, W Han, YH Chen, FR Wang, JZ Wang, Y Chen, CH Yan, MR Huo, D Li, XJ Huang. Who is the best donor for a related HLA haplotype-mismatched transplant? Blood 2014; 124(6): 843–850
https://doi.org/10.1182/blood-2014-03-563130
pmid: 24916508
|
17 |
XJ Huang, LP Xu, KY Liu, DH Liu, H Chen, W Han, YH Chen, JZ Wang, Yao Chen, XH Zhang, HX Shi, DP Lu. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase. Ann Med 2008; 40(6): 444–455
https://doi.org/10.1080/07853890801908903
pmid: 18608121
|
18 |
YZ Qin, YR Liu, HH Zhu, JL Li, GR Ruan, Y Zhang, Q Jiang, H Jiang, LD Li, Y Chang, XJ Huang, SS Chen. Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response. Int J Lab Hematol 2008; 30(4): 317–323
https://doi.org/10.1111/j.1751-553X.2007.00962.x
pmid: 18665830
|
19 |
Y Qin, S Chen, B Jiang, Q Jiang, H Jiang, J Li, L Li, Y Lai, Y Liu, X Huang. Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients. Ann Hematol 2011; 90(1): 47–52
https://doi.org/10.1007/s00277-010-1039-5
pmid: 20697894
|
20 |
XJ Huang, LP Xu, KY Liu, DH Liu, H Chen, YR Liu, YH Chen, W Han, Y Wang. Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia. Biol Blood Marrow Transplant 2011; 17(5): 649–656
|
21 |
XJ Huang, DH Liu, KY Liu, LP Xu, H Chen, W Han. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 2007; 92(3): 414–417
https://doi.org/10.3324/haematol.10570
pmid: 17339194
|
22 |
S Saussele, M Lauseker, A Gratwohl, DW Beelen, D Bunjes, R Schwerdtfeger, HJ Kolb, AD Ho, C Falge, E Holler, G Schlimok, AR Zander, R Arnold, L Kanz, R Dengler, C Haferlach, B Schlegelberger, M Pfirrmann, MC Müller, S Schnittger, A Leitner, N Pletsch, A Hochhaus, J Hasford, R Hehlmann; German CML Study Group. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010; 115(10): 1880–1885
https://doi.org/10.1182/blood-2009-08-237115
pmid: 19965667
|
23 |
HJ Khoury, M Kukreja, JM Goldman, T Wang, J Halter, M Arora, V Gupta, DA Rizzieri, B George, A Keating, RP Gale, DI Marks, PL McCarthy, A Woolfrey, J Szer, SA Giralt, RT Maziarz, J Cortes, MM Horowitz, SJ Lee. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. Bone Marrow Transplant 2012; 47(6): 810–816
https://doi.org/10.1038/bmt.2011.194
pmid: 21986636
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|